TrialCancer journal (Sudbury, Mass.)

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.

Lawrence Flaherty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.